XOMA Co. (NASDAQ:XOMA - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for XOMA in a report released on Wednesday, March 19th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will post earnings per share of ($0.20) for the quarter. HC Wainwright has a "Buy" rating and a $104.00 price target on the stock. The consensus estimate for XOMA's current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for XOMA's Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at $0.23 EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at $0.12 EPS.
XOMA (NASDAQ:XOMA - Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The company had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million.
Separately, StockNews.com upgraded XOMA from a "sell" rating to a "hold" rating in a report on Friday.
View Our Latest Research Report on XOMA
XOMA Trading Down 0.9 %
NASDAQ:XOMA traded down $0.19 during trading hours on Friday, hitting $20.74. The stock had a trading volume of 29,881 shares, compared to its average volume of 26,515. The business's 50 day moving average is $24.28 and its 200-day moving average is $27.08. The company has a market cap of $248.44 million, a price-to-earnings ratio of -5.96 and a beta of 1.00. XOMA has a one year low of $19.92 and a one year high of $35.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.
Insiders Place Their Bets
In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 7.20% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of XOMA. Geode Capital Management LLC lifted its holdings in XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company's stock valued at $4,840,000 after purchasing an additional 1,138 shares during the last quarter. Woodline Partners LP raised its position in shares of XOMA by 63.9% in the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company's stock valued at $4,107,000 after purchasing an additional 60,927 shares during the period. State Street Corp lifted its stake in shares of XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company's stock worth $3,783,000 after buying an additional 1,754 shares during the last quarter. Eversept Partners LP boosted its holdings in shares of XOMA by 1.2% during the 4th quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company's stock worth $2,508,000 after buying an additional 1,128 shares during the period. Finally, Northern Trust Corp grew its stake in XOMA by 1.5% in the 4th quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company's stock valued at $2,396,000 after buying an additional 1,340 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.
About XOMA
(
Get Free Report)
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Featured Stories
Before you consider XOMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XOMA wasn't on the list.
While XOMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
